Literature DB >> 11382591

The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors.

G Neufeld1, O Kessler, Z Vadasz, Z Gluzman-Poltorak.   

Abstract

Vascular endothelial growth factor is a major inducer of angiogenesis and a vascular permeability inducing factor. Its expression is upregulated in many types of tumors and it is thought to be a major inducer of tumor angiogenesis. This article focuses on the role of vascular endothelial growth factor in tumor progression and on current efforts aimed at the inhibition of tumor progression through the inhibition of vascular endothelial growth factor activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11382591

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  7 in total

1.  The von Hippel-Lindau Tumor Suppressor Protein Is Destabilized by Src: Implications for Tumor Angiogenesis and Progression.

Authors:  Mary T-H Chou; Josephine Anthony; Jeffrey D Bjorge; Donald J Fujita
Journal:  Genes Cancer       Date:  2010-03-22

2.  IL-1 is required for tumor invasiveness and angiogenesis.

Authors:  Elena Voronov; Dror S Shouval; Yakov Krelin; Emanuela Cagnano; Daniel Benharroch; Yoichiro Iwakura; Charles A Dinarello; Ron N Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-21       Impact factor: 11.205

3.  Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer.

Authors:  Hubert G Hotz; O Joe Hines; Birgit Hotz; Thomas Foitzik; Heinz J Buhr; Howard A Reber
Journal:  J Gastrointest Surg       Date:  2003-02       Impact factor: 3.452

4.  A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.

Authors:  Nikol Snoeren; Emile E Voest; Andre M Bergman; Otilia Dalesio; Henk M Verheul; Rob A E M Tollenaar; Joost R M van der Sijp; Sander B Schouten; Inne H M Borel Rinkes; R van Hillegersberg
Journal:  BMC Cancer       Date:  2010-10-11       Impact factor: 4.430

Review 5.  Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review.

Authors:  T O'Hare; R McDermott; R Hannon
Journal:  Ir J Med Sci       Date:  2017-08-29       Impact factor: 1.568

Review 6.  The role of antiangiogenesis therapy: bevacizumab and beyond.

Authors:  Hernán Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2009-06       Impact factor: 3.405

7.  Mast Cell Proteases 6 and 7 Stimulate Angiogenesis by Inducing Endothelial Cells to Release Angiogenic Factors.

Authors:  Devandir Antonio de Souza Junior; Antonio Carlos Borges; Ana Carolina Santana; Constance Oliver; Maria Célia Jamur
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.